The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates
Open accessAbstract
CA 19-9 and CEA are the most commonly used biomarkers for diagnosis and management of patients with pancreatic cancer. Since the original compendium by Steinberg in 1990, numerous studies have reported the use of CA 19-9 and, to a lesser extent, CEA in the diagnosis of pancreatic cancer. Here we update an evaluation of the accuracy of CA 19-9 and CEA, and, unlike previous reviews, focus on discrimination between malignant and benign disease instead of normal controls. In 57 studies involving 3,285 pancreatic carcinoma cases, the combined sensitivity of CA 19-9 was 78.2% and in 37 studies involving 1,882 cases with benign pancreatic disease the specificity of CA 19-9 was 82.8%. From the combined analysis of studies reporting CEA, the sensitivity was 44.2% (1,324 cases) and the specificity was 84.8% (656 cases). These measurements more appropriately reflect the expected biomarker accuracy in the differential diagnosis of patients with periampullary diseases. We also present a summary of the use of CA 19-9 as a prognostic tool and evaluate CA 19-9 diagnostic and prognostic utility in a 10-year, single institution experience.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“The random effects method described by DerSimonian and Laird was used to model sensitivity and specificity [15].”
MethodASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M., Kemeny, N., Macdonald, J. S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2644 · Cited by 1,592
Colorectal carcinoma antigens detected by hybridoma antibodies
Koprowski, H., Steplewski, Z., Mitchell, K., Herlyn, M., Herlyn, D., & Fuhrer, P. (1979) · Somatic Cell Genetics · doi:10.1007/bf01542654 · Cited by 1,364
Goonetilleke, K. S., & Siriwardena, A. K. (2007) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2006.10.004 · Cited by 877
Specific Antigen in Serum of Patients with Colon Carcinoma
Koprowski, H., Herlyn, M., Steplewski, Z., & Sears, H. F. (1981) · Science · doi:10.1126/science.6163212 · Cited by 591
(1990) · PubMed · Cited by 579
Ferrone, C. R., Finkelstein, D. M., Thayer, S. P., Muzikansky, A., Castillo, C. F.-D., & Warshaw, A. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3934 · Cited by 554
Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9.
Del Villano, B. C., Brennan, S., Brock, P., Bucher, C., Liu, V, McClure, M., Rake, B., Space, S., Westrick, B., Schoemaker, H., et al. (1983) · Clinical Chemistry · doi:10.1093/clinchem/29.3.549 · Cited by 506
Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.
Tempero, M. A., Uchida, E., Takasaki, H., Burnett, D. A., Steplewski, Z., & Pour, P. M. (1987) · PubMed · Cited by 400
KIM, J., LEE, K. T., LEE, J. K., PAIK, S. W., RHEE, J. C., & CHOI, K. W. (2004) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2004.03219.x · Cited by 394
Berger, A. C., Garcia, M., Hoffman, J. P., Regine, W. F., Abrams, R. A., Safran, H., Konski, A., Benson, A. B., MacDonald, J., & Willett, C. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.6288 · Cited by 371
The prognostic and predictive value of serum CA19.9 in pancreatic cancer
Humphris, J. L., Chang, D. K., Johns, A. L., Scarlett, C. J., Pajic, M., Jones, M. D., Colvin, E. K., Nagrial, A., Chin, V. T., Chantrill, L. A., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr561 · Cited by 312
Ni, X. G., Bai, X. F., Mao, Y. L., Shao, Y. F., Wu, J. X., Shan, Y., Wang, C. F., Wang, J., Tian, Y. T., Liu, Q., et al. (2005) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2004.09.007 · Cited by 303
Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice
Mann, D., Edwards, R., Ho, S., Lau, W., & Glazer, G. (2000) · European Journal of Surgical Oncology (EJSO) · doi:10.1053/ejso.1999.0925 · Cited by 294
Screening for Pancreatic Cancer: Why, How, and Who?
Poruk, K. E., Firpo, M. A., Adler, D. G., & Mulvihill, S. J. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e31825ffbfb · Cited by 249 · cited 2×
“performance over CA 19-9 for PDAC diagnosis and monitoring has been a research priority in recent years (reviewed in [6]).”
BackgroundSelf-citationSteinberg, W. M., Gelfand, R., Anderson, K. K., Glenn, J., Kurtzman, S. H., Sindelar, W. F., & Toskes, P. P. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90930-3 · Cited by 215
Koopmann, J., Rosenzweig, C. N. W., Zhang, Z., Canto, M. I., Brown, D. A., Hunter, M., Yeo, C., Chan, D. W., Breit, S. N., & Goggins, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0564 · Cited by 213
Kim, H. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00290-7 · Cited by 198
Halm, U., Schumann, T., Schiefke, I., Witzigmann, H., Mössner, J., & Keim, V (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1035 · Cited by 197
Maithel, S. K., Maloney, S., Winston, C., Gönen, M., D’Angelica, M. I., DeMatteo, R. P., Jarnagin, W. R., Brennan, M. F., & Allen, P. J. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0134-5 · Cited by 190
Evaluation of a Serologic Marker, CA19-9, in the Diagnosis of Pancreatic Cancer
Pleskow, D. K., Berger, H. J., Gyves, J., Allen, E., McLean, A., & Podolsky, D. K. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-9-704 · Cited by 184
Boeck, S., Stieber, P., Holdenrieder, S., Wilkowski, R., & Heinemann, V. (2006) · Oncology · doi:10.1159/000094888 · Cited by 172
Kondo, N., Murakami, Y., Uemura, K., Hayashidani, Y., Sudo, T., Hashimoto, Y., Nakashima, A., Sakabe, R., Shigemoto, N., Kato, Y., et al. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1033-0 · Cited by 169
Jalanko, H., Kuusela, P., Roberts, P., Sipponen, P., Haglund, C. A., & Mäkelä, O. (1984) · Journal of Clinical Pathology · doi:10.1136/jcp.37.2.218 · Cited by 162
Duraker, N., Hot, S., Polat, Y., Hobek, A. A., Gençler, N., & Urhan, N. (2007) · Journal of Surgical Oncology · doi:10.1002/jso.20604 · Cited by 156
Ehmann, M., Felix, K., Hartmann, D., Schnölzer, M., Nees, M., Vorderwülbecke, S., Bogumil, R., Büchler, M. W., & Friess, H. (2007) · Pancreas · doi:10.1097/01.mpa.0000250128.57026.b2 · Cited by 150
Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinoma
Reni, M., Cereda, S., Balzano, G., Passoni, P., Rognone, A., Fugazza, C., Mazza, E. A., Zerbi, A., Carlo, V. D., & Villa, E. (2009) · Cancer · doi:10.1002/cncr.24302 · Cited by 125
Hata, S., Sakamoto, Y., Yamamoto, Y., Nara, S., Esaki, M., Shimada, K., & Kosuge, T. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2020-9 · Cited by 109
Cancer Antigens 19-9 and 125 in the Differential Diagnosis of Pancreatic Mass Lesions
Ćwik, G., Wallner, G., Skoczylas, T., Ciechański, A., & Zinkiewicz, K. (2006) · Archives of Surgery · doi:10.1001/archsurg.141.10.968 · Cited by 108
Sakamoto, K., Haga, Y., Yoshimura, R., Egami, H., Yokoyama, Y., & Akagi, M. (1987) · Gut · doi:10.1136/gut.28.3.323 · Cited by 101
Malesci, A., Tommasini, M., Bonato, C., Bocchia, P., Bersani, M., Zerbi, A., Beretta, E., & Carlo, V. D. (1987) · Gastroenterology · doi:10.1016/0016-5085(87)90840-7 · Cited by 100
Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma
Barton, J. G., Bois, J. P., Sarr, M. G., Wood, C. M., Qin, R., Thomsen, K. M., Kendrick, M. L., & Farnell, M. B. (2009) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-009-0849-z · Cited by 93
Ong, S. L., Sachdeva, A., Garcea, G., Gravante, G. G., Metcalfe, M. S., Lloyd, D., Berry, D. P., & Dennison, A. R. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0289-8 · Cited by 93
Safi, F., Schlosser, W., Kolb, G., & Beger, H. G. (1997) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(97)80097-2 · Cited by 89
CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer
Willett, C. G., Daly, W. J., & Warshaw, A. L. (1996) · The American Journal of Surgery · doi:10.1016/s0002-9610(97)89547-5 · Cited by 85
Ozkan, H., Kaya, M., & Cengiz, A. (2003) · PubMed · Cited by 71
Chang, M., Chang, Y., Su, T., Yang, W., Chen, C., Tien, Y., Liang, P., Wei, S., & Wong, J. (2007) · Pancreas · doi:10.1097/mpa.0b013e3180547709 · Cited by 69
Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang, X., Tao, H., & Zou, S.-C. (2004) · PubMed · Cited by 68
Slesak, B., Harłoziñska-Szmyrka, A., Knast, W., Sedlaczek, P., van Dalen, A., & EINARSSON, R. (2000) · Cancer · Cited by 68
Takasaki, H., Uchida, E., Tempero, M. A., Burnett, D. A., Metzgar, R. S., & Pour, P. M. (1988) · PubMed · Cited by 68
Benini, L., Cavallini, G., Zordan, D., Rizzotti, P., Rigo, L., Brocco, G., Perobelli, L., Zanchetta, M., Pederzoli, P., & Scuro, L. A. (1988) · Pancreas · doi:10.1097/00006676-198802000-00011 · Cited by 61
Dianxu, F., Shengdao, Z., Tianquan, H., Yu, J., Ruoqing, L., Zurong, Y., & Wang, X. (2002) · Pancreas · doi:10.1097/00006676-200211000-00003 · Cited by 59
CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
Morris‐Stiff, G. J., Teli, M., Jardine, N., & Puntis, M. C. A. (2009) · PubMed · Cited by 58
Cerwenka, H., Aigner, R., Bacher, H., Werkgartner, G., El-Shabrawi, A., Quehenberger, F., & Mischinger, H. J. (1999) · PubMed · Cited by 55
Hernandez, J. M., Cowgill, S. M., Al-Saadi, S., Collins, A., Ross, S. B., Cooper, J., Villadolid, D., Zervos, E. E., & Rosemurgy, A. S. (2008) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-008-0696-3 · Cited by 54
Liao, Q., Zhao, Y.-P., Yang, Y., Li, L., Long, X. R., & Han, S. (2007) · PubMed · Cited by 53
Firpo, M. A., Gay, D. Z., Granger, S. R., Scaife, C. L., DiSario, J. A., Boucher, K. M., & Mulvihill, S. J. (2008) · World Journal of Surgery · doi:10.1007/s00268-008-9853-9 · Cited by 53
Serum Heat Shock Protein 27 Is Increased in Chronic Pancreatitis and Pancreatic Carcinoma
Liao, W., Wu, M., Wang, H., Tien, Y., & Lin, J. (2009) · Pancreas · doi:10.1097/mpa.0b013e318198281d · Cited by 47
p53 Autoantibodies in Patients with Pancreatitis and Pancreatic Carcinoma
Raedle, J., Oremek, G. M., Welker, M., Roth, W. K., Caspary, W. F., & Zeuzem, S. (1996) · Pancreas · doi:10.1097/00006676-199610000-00005 · Cited by 46
Voorhess, M. L., Brecher, M. L., Glicksman, A. S., Jones, B., Harris, M., Krischer, J. P., Boyett, J. M., Forman, E. N., & Freeman, A. I. (1986) · Cancer · doi:10.1002/1097-0142(19860401)57:7<1324::aid-cncr2820570712>3.0.co;2-a · Cited by 45
Boeck, S. H., Haas, M., Laubender, R. P., Kullmann, F., Klose, C., Bruns, C. J., Wilkowski, R., Stieber, P., Holdenrieder, S., Buchner, H., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2205 · Cited by 41
Satake, K., Kanazawa, G., Kho, I., Chung, Y.-S., & Umeyama, K. (1985) · PubMed · Cited by 37
Evaluation of Carbohydrate Antigens 19-9 and 12-5 in Patients with Pancreatic Cancer
Pasquali, C., Sperti, C., DʼAndrea, A. A., Bonadimani, B., Favero, G. D., Petrin, P., & Pedrazzoli, S. (1987) · Pancreas · doi:10.1097/00006676-198701000-00005 · Cited by 22
Comparison of Plasma Tu-M2-PK and CA19-9 in Pancreatic Cancer
Jøergensen, M. T., Heegaard, N. H. H., & de Muckadell, O. B. S. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181bae8ab · Cited by 20
Hedström, J., Haglund, C. H., Kemppainen, E., Leinimaa, M., Leinonen, J., & Stenman, U. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.10.1768 · Cited by 18
Nishida, K., Tasaki, N., MIYAGAWA, H., Yoshikawa, T., & Kondo, M. (1988) · PubMed · Cited by 15
Androstanediol Glucuronide in Patients with Pancreatic Cancer and in Those with Chronic Pancreatitis
Janša, R., Preželj, J., Kocijancic, A., Osredkar, J., & Ferlic, F. (1996) · Hormone and Metabolic Research · doi:10.1055/s-2007-979820 · Cited by 7
Cited by
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982
New Technologies for Analysis of Extracellular Vesicles
Shao, H., Im, H., Castro, C. M., Breakefield, X., Weissleder, R., & Lee, H. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00534 · Cited by 1,675
Electrochemical Methods for the Analysis of Clinically Relevant Biomolecules
Labib, M., Sargent, E. H., & Kelley, S. O. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00220 · Cited by 976
Allenson, K., Castillo, J., San Lucas, F. A., Scelo, G., Kim, D. U., Bernard, V., Davis, G., Kumar, T., Katz, M., Overman, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx004 · Cited by 493
Rodriguez, E., Boelaars, K., Brown, K., Eveline Li, R. J., Kruijssen, L., Bruijns, S. C. M., van Ee, T., Schetters, S. T. T., Crommentuijn, M. H. W., van der Horst, J. C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21550-4 · Cited by 311
Self-citation
Metadata
- Authors
- E. Poruk, K., Z. Gay, D., Brown, K., D. Mulvihill, J., M. Boucher, K., L. Scaife, C., A. Firpo, M., & J. Mulvihill, S.
- Venue
- Current Molecular Medicine
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2013-02-01
- Volume
- 13
- Issue
- 3
- Pages
- 340-351
- ISSN
- 1566-5240 (ISSN-L)
- OpenAlex
- W2159407099
- Cited by
- 398
- References
- 57
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.